COMPUGEN LTDNARY SHARES
COMPUGEN LTDNARY SHARES
Action · IL0010852080 · CGEN · 553001 (XNMS)
Aperçu Indicateurs financiers
1,74 USD
-2,79 % -0,05 USD
NASDAQ/NMS (GLOBAL MARKET) (XNAS) · Cours et graphiques actuels sur MoneyPeak
11.06.2025 19:59

Cours actuels de COMPUGEN LTDNARY SHARES

BourseTickerDeviseDernier échangeCoursVariation journalière
XNAS: NASDAQ
NASDAQ
CGEN
USD
11.06.2025 19:59
1,74 USD
1,79 USD
-2,52 %

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
0,00 % 0,00 % 38,10 % 5,78 % 9,09 % -14,29 % -86,44 %

Profil de l'entreprise pour COMPUGEN LTDNARY SHARES Action

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Fonds investis

Les fonds suivants ont investi dans : COMPUGEN LTDNARY SHARES investi :

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. en millions
18,42
Part (%)
0,04 %

Données de l'entreprise

Nom COMPUGEN LTDNARY SHARES
Société Compugen Ltd.
Symbole CGEN
Site web https://cgen.com
Marché d'origine XNMS NASDAQ/NMS (GLOBAL MARKET)
WKN 553001
ISIN IL0010852080
Type de titre Action
Secteur Healthcare
Industrie Biotechnology
PDG Dr. Anat Cohen-Dayag Ph.D.
Capitalisation boursière 138 Mio
Pays Israël
Devise USD
Employés 0,1 T
Adresse Azrieli Center, 5885849 Holon
Date d'introduction en bourse 2000-08-11

Symboles boursiers

Nom Symbole
NASDAQ CGEN

Autres actions

Les investisseurs qui détiennent COMPUGEN LTDNARY SHARES ont également les actions suivantes dans leur portefeuille :
AMGEN INC
AMGEN INC Action
AUTODESK INC
AUTODESK INC Action
BIOGEN INC
BIOGEN INC Action
CISCO SYSTEMS INC
CISCO SYSTEMS INC Action
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Action
EBAY INC
EBAY INC Action
FG AMERICA ACQUISITION CORP UNITS
FG AMERICA ACQUISITION CORP UNITS Action
INTEL CORP
INTEL CORP Action
MICROSOFT CORP
MICROSOFT CORP Action
O'REILLY AUTOMOTIVE INC
O'REILLY AUTOMOTIVE INC Action
POSEIDA THERAPEUTICSCS INC
POSEIDA THERAPEUTICSCS INC Action
REGULUS THERAPEUTICSCS INC
REGULUS THERAPEUTICSCS INC Action
SUN CONTRACT 20/25
SUN CONTRACT 20/25 Obligation
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Action
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025